AP101P
Rabbit Anti-Human IgG Antibody, HRP conjugate
Chemicon®, from rabbit
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
rabbit
Quality Level
conjugate
peroxidase conjugate
antibody form
F(ab′)2 fragment of affinity isolated antibody
antibody product type
secondary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
western blot: suitable
shipped in
wet ice
target post-translational modification
unmodified
Related Categories
Application
Detect Human IgG using this Rabbit anti-Human IgG Antibody, HRP conjugate validated for use in ELISA & WB.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Biochemistry, 55(44), 6100-6114 (2016-10-13)
We recently reported the discovery of a recombinant chimera, denoted DAVEI (dual-acting virucidal entry inhibitor), which is able to selectively cause specific and potent lytic inactivation of both pseudotyped and fully infectious human immunodeficiency virus (HIV-1) virions. The chimera is
The Journal of clinical endocrinology and metabolism, 108(7), e474-e479 (2023-01-08)
Poor glucose control has been associated with increased mortality in COVID-19 patients with type 1 diabetes (T1D). This work aimed to assess the effect of prevaccination glucose control on antibody response to the SARS-CoV-2 vaccine BNT162b2 in T1D. We studied
Antigen discovery by bioinformatics analysis and peptide microarray for the diagnosis of cystic echinococcosis.
PLoS Neglected Tropical Diseases, 17, e0011210-e0011210 (2023)
medRxiv : the preprint server for health sciences (2020-08-21)
The global COVID-19 pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the SARS-CoV-2 spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive
The Biochemical journal, 475(5), 931-957 (2018-01-19)
We previously reported a first-generation recombinant DAVEI construct, a dual action virus entry inhibitor composed of cyanovirin-N (CVN) fused to a membrane proximal external region or its derivative peptide Trp3. DAVEI exhibits potent and irreversible inactivation of HIV-1 (human immunodeficiency
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service